Levi Garraway, Roche CMO

Roche snags an FDA ap­proval for an ad­vanced melanoma drug cock­tail — but it's up against some fierce com­pe­ti­tion

Roche’s PD-L1 in­hibitor Tecen­triq snagged an FDA ap­proval to treat cer­tain ad­vanced melanoma pa­tients in a three-drug cock­tail, pro­vid­ing an­oth­er op­tion for pa­tients with a typ­i­cal­ly poor prog­no­sis.

In a Phase III IM­spire150 study, Tecen­triq com­bined with Cotel­lic (co­bime­tinib) and Zelb­o­raf (ve­mu­rafenib) sig­nif­i­cant­ly beat a place­bo mix in ex­tend­ing pro­gres­sion-free sur­vival in BRAF V600 mu­ta­tion-pos­i­tive ad­vanced melanoma pa­tients. Par­tic­i­pants on Tecen­triq lived a me­di­an 15.1 months with­out wors­en­ing dis­ease, com­pared to 10.6 months in pa­tients on Cotel­lic, Zelb­o­raf, and the place­bo.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.